Format

Send to

Choose Destination
Curr Opin Cardiol. 2019 Mar;34(2):202-206. doi: 10.1097/HCO.0000000000000594.

Update on the diagnosis and management of acute heart failure.

Author information

1
Division of Cardiology, Canadian VIGOUR Centre, University of Alberta, Edmonton.
2
Division of Internal Medicine, University of Calgary, Calgary, Alberta, Canada.

Abstract

PURPOSE OF REVIEW:

To highlight the advances in the diagnosis and management of acute heart failure (AHF) from recent clinical trials and observational studies.

RECENT FINDINGS:

We highlight date from recent studies examining the use of novel biomarkers (micro RNAs, osteopontin, insulin-like growth-factor binding protein-7) for the diagnosis of AHF. In addition, we summarize the evidence for novel pharmacological therapies including: serelaxin, ularitide, clevidipine, urocortins, BMS-986231, TRB027, vericiguat, omecamtiv, and torsemide. Finally, we explore the evidence behind the use of novel management algorithms.

SUMMARY:

Despite many advances in understanding the pathophysiology of AHF, there is currently insufficient evidence to suggest changes to standards of care.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center